tiprankstipranks
Trending News
More News >
Crispr Therapeutics AG (CRSP)
NASDAQ:CRSP

Crispr Therapeutics AG (CRSP) AI Stock Analysis

Compare
9,505 Followers

Top Page

CR

Crispr Therapeutics AG

(NASDAQ:CRSP)

Rating:54Neutral
Price Target:
$49.00
▲(0.74%Upside)
The overall stock score reflects the significant financial challenges faced by Crispr Therapeutics AG, particularly in revenue generation and profitability, which are partially offset by a strong balance sheet and positive corporate events indicating strategic advancements. The technical analysis suggests potential short-term corrections due to overbought conditions, and valuation metrics highlight financial underperformance.
Positive Factors
Business Development Opportunities
Interest in gene editing, particularly for cardiovascular diseases, remains high, with potential opportunities for business development to validate CRISPR's technology.
In Vivo Gene Editing
The in vivo gene editing approach demonstrates promise with the updated CTX310 data showing competitive peak reductions for triglycerides and LDL, along with a solid safety profile.
Pipeline Development
CRISPR Therapeutics' diverse and robust pipeline, with key technologies passing through several derisking hoops, positions it well in the gene editing landscape.
Negative Factors
Competitive Positioning
CTX310 data shows encouraging knockdown, and debate now shifts to competitive position vs other TG/LDL lowering agents.
Delays in Data Release
Delaying CTX320 Lp(a) data - a catalyst to diversify the story beyond Casgevy commercial launch - is a disappointment.
Strategic Timing Concerns
CTX320 data is delayed until 1H26 due to strategic timing.

Crispr Therapeutics AG (CRSP) vs. SPDR S&P 500 ETF (SPY)

Crispr Therapeutics AG Business Overview & Revenue Model

Company DescriptionCrispr Therapeutics AG (CRSP) is a leading biotechnology company focused on developing transformative gene-based medicines. The company leverages CRISPR/Cas9 gene-editing technology to create therapies for serious diseases, with a primary focus on genetic disorders, oncology, and regenerative medicine. Crispr Therapeutics has a robust pipeline of innovative product candidates designed to address unmet medical needs across various therapeutic areas.
How the Company Makes MoneyCrispr Therapeutics AG generates revenue primarily through collaborations and strategic partnerships with other pharmaceutical and biotechnology companies. These partnerships often involve upfront payments, milestone payments, and royalties on sales resulting from successful commercialization of jointly developed therapies. Additionally, Crispr Therapeutics may receive research grants and government funding to support its development of gene-editing therapies. The company also aims to commercialize its own drug candidates, which, upon regulatory approval, would provide another revenue stream in the form of product sales.

Crispr Therapeutics AG Key Performance Indicators (KPIs)

Any
Any
Revenue by Segment
Revenue by Segment
Analyzes income from different business areas, highlighting which segments drive growth and profitability, and where the company might be vulnerable or have opportunities for expansion.
Chart InsightsCrispr Therapeutics AG's revenue from collaborations has been highly volatile, with significant spikes in certain quarters, notably in late 2023 and early 2024, suggesting irregular but substantial partnership deals. Meanwhile, grant revenue has remained minimal and relatively stable, indicating limited reliance on this segment. The absence of earnings call commentary leaves the reasons for these fluctuations unclear, but the pattern suggests strategic partnerships are a key driver of revenue, albeit inconsistently. Investors should watch for announcements on new collaborations to gauge future revenue potential.
Data provided by:Main Street Data

Crispr Therapeutics AG Financial Statement Overview

Summary
Crispr Therapeutics AG faces significant financial challenges with negative income and cash flow metrics, underscoring operational inefficiencies and revenue generation issues. Despite a strong balance sheet with high equity and cash reserves, the company's negative free cash flow trend and reliance on external funding indicate potential liquidity challenges.
Income Statement
45
Neutral
Crispr Therapeutics AG has shown significant volatility in revenue and profit margins. The most recent annual report indicates a drastic revenue decline compared to previous years, with a sharp drop from 2021 to 2024. Gross and net profit margins have turned negative, highlighting operational challenges and high expenses relative to revenue. The TTM data shows a negative EBIT and EBITDA margin, indicating operational inefficiencies and ongoing financial struggles.
Balance Sheet
65
Positive
The company maintains a strong equity position with a high equity ratio, suggesting stability in its capital structure. While the debt-to-equity ratio is relatively low, indicating manageable leverage, the stockholders' equity has slightly declined over the years. The balance sheet reflects a solid cash position, which is crucial for a biotech firm investing in R&D, despite the negative net income.
Cash Flow
50
Neutral
Crispr Therapeutics AG exhibits a negative free cash flow trend, with operating cash flows consistently negative over recent years. This indicates potential liquidity challenges. The free cash flow to net income ratio is also negative, underscoring ongoing cash management issues. The cash flow from financing has been positive, which may provide temporary relief but signifies reliance on external funding.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue36.98M35.00M371.21M436.00K913.08M543.00K
Gross Profit-88.65M-75.25M240.96M-109.81M895.13M-268.86M
EBITDA-455.24M-447.31M-202.70M-648.99M391.48M-345.25M
Net Income-385.66M-366.25M-153.61M-650.17M377.66M-348.87M
Balance Sheet
Total Assets2.17B2.24B2.23B2.24B2.75B1.83B
Cash, Cash Equivalents and Short-Term Investments1.86B1.90B1.69B1.82B2.38B1.69B
Total Debt219.36M223.69M238.63M244.02M225.03M61.43M
Total Liabilities336.94M309.95M346.77M367.58M352.42M163.73M
Stockholders Equity1.83B1.93B1.88B1.88B2.40B1.66B
Cash Flow
Free Cash Flow-307.86M-144.68M-272.35M-532.93M457.27M-256.72M
Operating Cash Flow-306.47M-142.77M-260.38M-495.74M538.97M-238.37M
Investing Cash Flow-202.44M-280.48M374.65M-258.65M-1.04B-541.17M
Financing Cash Flow36.64M331.98M62.66M38.59M250.94M1.02B

Crispr Therapeutics AG Technical Analysis

Technical Analysis Sentiment
Positive
Last Price48.64
Price Trends
50DMA
39.58
Positive
100DMA
40.36
Positive
200DMA
43.15
Positive
Market Momentum
MACD
2.52
Negative
RSI
74.63
Negative
STOCH
78.46
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRSP, the sentiment is Positive. The current price of 48.64 is above the 20-day moving average (MA) of 42.95, above the 50-day MA of 39.58, and above the 200-day MA of 43.15, indicating a bullish trend. The MACD of 2.52 indicates Negative momentum. The RSI at 74.63 is Negative, neither overbought nor oversold. The STOCH value of 78.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CRSP.

Crispr Therapeutics AG Risk Analysis

Crispr Therapeutics AG disclosed 85 risk factors in its most recent earnings report. Crispr Therapeutics AG reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Crispr Therapeutics AG Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
78
Outperform
$1.84B12.0524.71%20.62%14.08%
54
Neutral
$4.10B-19.71%-86.13%-67.29%
52
Neutral
$1.01B-34.26%271.44%26.65%
51
Neutral
$1.64B-70.58%100.03%64.22%
51
Neutral
$7.44B0.40-61.90%2.33%17.14%1.55%
50
Neutral
$990.26M-57.92%-13.37%2.57%
45
Neutral
$1.69B-38.04%-82.38%-164.76%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CRSP
Crispr Therapeutics AG
48.64
-5.31
-9.84%
NTLA
Intellia Therapeutics
9.38
-13.09
-58.26%
ARQT
Arcutis Biotherapeutics
14.02
4.46
46.65%
BEAM
Beam Therapeutics
17.01
-6.04
-26.20%
HRMY
Harmony Biosciences Holdings
31.60
1.18
3.88%
VERV
Verve Therapeutics
11.23
6.25
125.50%

Crispr Therapeutics AG Corporate Events

Product-Related AnnouncementsBusiness Operations and Strategy
CRISPR Therapeutics Updates on Cardiovascular Programs
Positive
Jun 26, 2025

On June 26, 2025, CRISPR Therapeutics AG announced updates on its in vivo cardiovascular disease programs, including new data for CTX310™, CTX320™, and CTX340™. CTX310™, targeting ANGPTL3, continues to show promising results in reducing triglycerides and low-density lipoprotein in its Phase 1 trial, with peak reductions of up to 82% and 86% respectively, without significant liver enzyme changes. CTX320™, targeting the LPA gene, is in an ongoing Phase 1 trial, with an update expected in the first half of 2026. Meanwhile, CTX340™, targeting angiotensinogen for refractory hypertension, is progressing through preclinical studies. These developments highlight CRISPR Therapeutics AG’s strategic advancements in addressing cardiovascular diseases, potentially impacting its market position and offering new treatment avenues for patients.

The most recent analyst rating on (CRSP) stock is a Hold with a $59.00 price target. To see the full list of analyst forecasts on Crispr Therapeutics AG stock, see the CRSP Stock Forecast page.

Shareholder MeetingsBusiness Operations and Strategy
CRISPR Therapeutics AG Shareholders Approve Key Proposals
Positive
Jun 9, 2025

On June 5, 2025, CRISPR Therapeutics AG held its Annual General Meeting where shareholders approved several key proposals, including amendments to the company’s Articles of Association, financial statements for 2024, and the re-election of board members and auditors. These decisions, effective upon registration, are expected to strengthen the company’s governance and operational framework, potentially enhancing its strategic positioning in the biotechnology sector.

The most recent analyst rating on (CRSP) stock is a Hold with a $59.00 price target. To see the full list of analyst forecasts on Crispr Therapeutics AG stock, see the CRSP Stock Forecast page.

Product-Related AnnouncementsBusiness Operations and Strategy
Crispr Therapeutics AG Partners with Sirius on siRNA Tech
Positive
May 19, 2025

On May 19, 2025, CRISPR Therapeutics AG announced a collaboration agreement with Sirius Therapeutics to co-develop and commercialize siRNA technology targeting Factor XI, with an upfront consideration of $95 million. The agreement includes the development of SRSD107, a next-generation siRNA designed to inhibit coagulation factor XI, showing promising results in Phase 1 trials with potential applications in various thrombotic conditions. The collaboration aims to leverage SRSD107’s potential to reduce thrombotic events while minimizing bleeding risks, positioning it as a differentiated therapy in the market.

The most recent analyst rating on (CRSP) stock is a Hold with a $59.00 price target. To see the full list of analyst forecasts on Crispr Therapeutics AG stock, see the CRSP Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 26, 2025